BHVN
Price
$17.03
Change
+$0.83 (+5.12%)
Updated
Jun 6 closing price
Capitalization
1.74B
58 days until earnings call
OCUL
Price
$9.02
Change
+$0.56 (+6.62%)
Updated
Jun 6 closing price
Capitalization
1.44B
65 days until earnings call
Interact to see
Advertisement

BHVN vs OCUL

Header iconBHVN vs OCUL Comparison
Open Charts BHVN vs OCULBanner chart's image
Biohaven
Price$17.03
Change+$0.83 (+5.12%)
Volume$1.47M
Capitalization1.74B
Ocular Therapeutix
Price$9.02
Change+$0.56 (+6.62%)
Volume$2.15M
Capitalization1.44B
BHVN vs OCUL Comparison Chart
Loading...
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BHVN vs. OCUL commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHVN is a StrongBuy and OCUL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (BHVN: $17.03 vs. OCUL: $9.02)
Brand notoriety: BHVN and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BHVN: 63% vs. OCUL: 121%
Market capitalization -- BHVN: $1.74B vs. OCUL: $1.44B
BHVN [@Biotechnology] is valued at $1.74B. OCUL’s [@Biotechnology] market capitalization is $1.44B. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHVN’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • BHVN’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than BHVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHVN’s TA Score shows that 4 TA indicator(s) are bullish while OCUL’s TA Score has 6 bullish TA indicator(s).

  • BHVN’s TA Score: 4 bullish, 4 bearish.
  • OCUL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than BHVN.

Price Growth

BHVN (@Biotechnology) experienced а +14.99% price change this week, while OCUL (@Biotechnology) price change was +12.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

BHVN is expected to report earnings on Aug 04, 2025.

OCUL is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BHVN($1.74B) has a higher market cap than OCUL($1.44B). OCUL YTD gains are higher at: 5.621 vs. BHVN (-54.404). OCUL has higher annual earnings (EBITDA): -176.35M vs. BHVN (-877.26M). BHVN has more cash in the bank: 486M vs. OCUL (350M). BHVN has less debt than OCUL: BHVN (36.6M) vs OCUL (76.2M). OCUL has higher revenues than BHVN: OCUL (59.6M) vs BHVN (0).
BHVNOCULBHVN / OCUL
Capitalization1.74B1.44B121%
EBITDA-877.26M-176.35M497%
Gain YTD-54.4045.621-968%
P/E RatioN/AN/A-
Revenue059.6M-
Total Cash486M350M139%
Total Debt36.6M76.2M48%
FUNDAMENTALS RATINGS
BHVN vs OCUL: Fundamental Ratings
BHVN
OCUL
OUTLOOK RATING
1..100
522
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
10087
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
9442
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (53) in the Pharmaceuticals Other industry is in the same range as BHVN (56) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to BHVN’s over the last 12 months.

OCUL's Profit vs Risk Rating (87) in the Pharmaceuticals Other industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to BHVN’s over the last 12 months.

OCUL's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as BHVN (97) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to BHVN’s over the last 12 months.

OCUL's Price Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for BHVN (94) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew somewhat faster than BHVN’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to BHVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHVNOCUL
RSI
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
75%
Bearish Trend 16 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSMIX30.200.33
+1.10%
NYLI WMC Value Investor Class
VDSCX18.56N/A
N/A
Victory Diversified Stock C
NEXIX32.04N/A
N/A
Shelton Sustainable Equity Institutional
APGZX112.95N/A
N/A
AB Large Cap Growth Z
LGMNX25.26N/A
N/A
Loomis Sayles Global Allocation N

BHVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHVN has been loosely correlated with BEAM. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BHVN jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHVN
1D Price
Change %
BHVN100%
+5.12%
BEAM - BHVN
50%
Loosely correlated
+9.26%
CGON - BHVN
49%
Loosely correlated
+1.05%
SYRE - BHVN
49%
Loosely correlated
+2.11%
RVMD - BHVN
47%
Loosely correlated
+2.21%
OCUL - BHVN
47%
Loosely correlated
+6.62%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+6.62%
EYPT - OCUL
59%
Loosely correlated
+8.36%
DNLI - OCUL
50%
Loosely correlated
+3.38%
YMAB - OCUL
49%
Loosely correlated
+3.33%
NRIX - OCUL
48%
Loosely correlated
+2.24%
ERAS - OCUL
48%
Loosely correlated
+1.91%
More